Introduction
Results
Creation of BMP agonist reporter cells for high-throughput screening (HTS)

Identification of BMP signaling agonists via a cell-based HTS


p-SMAD-1/5/9 is induced by BMP signaling agonists

Noggin and type I BMP receptor inhibition is bypassed by sb4

BMP signaling efficacy is enhanced and maintained with sb4 treatment


Analogs of sb4 increase BMP signaling dose-dependently

Discussion
Experimental procedures
Construction of BMP reporter cells and cell culture
Small-molecule screening library
sb4 analog similarity search
Immunoblotting
Luciferase assays
BRE-Luc cell transcriptome profiling
Quantitative RT-PCR
Statistical analysis
Author contributions
Acknowledgments
Supplementary Material
References
- BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning.Genes Dev. 1995; 9 (7590255): 2808-2820
- BMP10 is essential for maintaining cardiac growth during murine cardiogenesis.Development. 2004; 131 (15073151): 2219-2231
- Smad1 and its target gene Wif1 coordinate BMP and Wnt signaling activities to regulate fetal lung development.Development. 2011; 138 (21270055): 925-935
- TGF-β family signaling in neural and neuronal differentiation, development, and function.Cold Spring Harb. Perspect Biol. 2017; 9 (28130363)a022244
- Bone morphogenetic protein (BMP) signaling in development and human diseases.Genes Dis. 2014; 1 (25401122): 87-105
- Bone morphogenetic protein receptor signal transduction in human diseases.J. Pathol. 2019; 247 (30246251): 9-20
- BMP-2 restoration aids in recovery from liver fibrosis by attenuating TGF-β1 signaling.Lab. Invest. 2018; 98 (29789683): 999-1013
- Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function.J. Am. Soc. Nephrol. 2002; 13 (11792757): S14-S21
- Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models.Am. J. Physiol. Renal Physiol. 2003; 285 (12915382): F1060-F1067
- Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.Nat. Med. 2007; 13 (17660828): 952-961
- Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis.Am. J. Respir. Crit. Care Med. 2008; 177 (17975199): 321-329
- FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.J. Clin. Invest. 2013; 123 (23867624): 3600-3613
- Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.Nat. Med. 2015; 21 (26076038): 777-785
- ACVR1 mutations in DIPG: lessons learned from FOP.Cancer Res. 2014; 74 (25136070): 4565-4570
- BMP-7 signaling and its critical roles in kidney development, the responses to renal injury, and chronic kidney disease.Vitam. Horm. 2015; 99 (26279374): 91-144
- BMP4 substitutes for loss of BMP7 during kidney development.Dev. Biol. 2005; 286 (16154126): 637-646
- BMP signalling in skeletal development, disease and repair.Nat. Rev. Endocrinol. 2016; 12 (26893264): 203-221
- Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells.J. Biol. Chem. 1999; 274 (10391928): 19838-19845
- Id: a target of BMP signaling.Sci. STKE. 2002; 2002 (12297674): pe40
- Dorsoventral patterning in Xenopus: inhibition of ventral signals by direct binding of chordin to BMP-4.Cell. 1996; 86 (8752213): 589-598
- The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4.Cell. 1996; 86 (8752214): 599-606
- Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease.Nat. Med. 2005; 11 (15793581): 387-393
- Kielin/chordin-like protein attenuates both acute and chronic renal injury.J. Am. Soc. Nephrol. 2013; 24 (23539757): 897-905
- The kielin/chordin-like protein KCP attenuates nonalcoholic fatty liver disease in mice.Am. J. Physiol. Gastrointest. Liver Physiol. 2016; 311 (27514479): G587-G598
- The kielin/chordin-like protein (KCP) attenuates high-fat diet-induced obesity and metabolic syndrome in mice.J. Biol. Chem. 2017; 292 (28424263): 9051-9062
- Development and optimization of a cell-based assay for the selection of synthetic compounds that potentiate bone morphogenetic protein-2 activity.Cell Biochem. Funct. 2009; 27 (19862690): 526-534
- A synthetic compound that potentiates bone morphogenetic protein-2-induced transdifferentiation of myoblasts into the osteoblastic phenotype.Mol. Cell Biochem. 2011; 349 (21110071): 97-106
- Selective small molecule compounds increase BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation.Sci. Rep. 2014; 4 (24828823)4965
- Quinoline compound KM11073 enhances BMP-2-dependent osteogenic differentiation of C2C12 cells via activation of p38 signaling and exhibits in vivo bone forming activity.PLoS One. 2015; 10 (25789987)e0120150
- Ventromorphins: a new class of small molecule activators of the canonical BMP signaling pathway.ACS Chem. Biol. 2017; 12 (28787124): 2436-2447
- Identification of small molecule activators of BMP signaling.PLoS One. 2013; 8 (23527084)e59045
- Discovery of a small-molecule BMP sensitizer for human embryonic stem cell differentiation.Cell Rep. 2016; 15 (27210748): 2063-2075
- Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway.Stem Cells Dev. 2010; 19 (19642865): 557-568
- Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.Nat. Chem. Biol. 2008; 4 (18026094): 33-41
- In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.ACS Chem. Biol. 2010; 5 (20020776): 245-253
- Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors.Bioorg. Med. Chem. Lett. 2008; 18 (18621530): 4388-4392
- Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.Bone. 2018; 109 (28918311): 251-258
- Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter.J. Biol. Chem. 2002; 277 (11729207): 4883-4891
- New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.J. Med. Chem. 2010; 53 (20131845): 2719-2740
- Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity.Drug. Discov. Today. 2010; 15 (20570751): 648-655
- MScreen: an integrated compound management and high-throughput screening data storage and analysis system.J. Biomol. Screen. 2012; 17 (22706349): 1080-1087
- Inhibition of Pax2 transcription activation with a small molecule that targets the DNA binding domain.ACS Chem. Biol. 2017; 12 (28094913): 724-734
- BMP type I receptor inhibition reduces heterotopic [corrected] ossification.Nat. Med. 2008; 14 (19029982): 1363-1369
- Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies.Kidney Int. 2007; 71 (17183245): 325-335
- Expression of gremlin, a bone morphogenetic protein antagonist, in glomerular crescents of pauci-immune glomerulonephritis.Nephrol. Dial. Transplant. 2007; 22 (17403698): 1882-1890
- Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy.Am. J. Kidney Dis. 2005; 45 (15957132): 1034-1039
- BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression.J. Histochem. Cytochem. 2009; 57 (19255250): 623-631
- Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease.Pediatr. Nephrol. 2008; 23 (18446379): 1395-1398
- Characterization of receptors for osteogenic protein-1/bone morphogenetic protein-7 (OP-1/BMP-7) in rat kidneys.Kidney Int. 2000; 58 (11044210): 1902-1911
- A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned.Spine J. 2011; 11 (21729796): 471-491
- Histopathologic inflammatory response induced by recombinant bone morphogenetic protein-2 causing radiculopathy after transforaminal lumbar interbody fusion.Spine J. 2010; 10 (20797648): e1-e6
- Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion Report of 4 cases.J. Neurosurg. Spine. 2010; 12 (20043763 20043763): 40-46
- A Smad action turnover switch operated by WW domain readers of a phosphoserine code.Genes Dev. 2011; 25 (21685363): 1275-1288
- Unique players in the BMP pathway: small C-terminal domain phosphatases dephosphorylate Smad1 to attenuate BMP signaling.Proc. Natl. Acad. Sci. U.S.A. 2006; 103 (16882717): 11940-11945
- Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-β pathways.J. Biol. Chem. 2006; 281 (17085434): 40412-40419
- A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation.Nature. 1999; 400 (10458166): 687-693
- Phosphatases in SMAD regulation.FEBS Lett. 2012; 586 (22576046): 1897-1905
- Balancing BMP signaling through integrated inputs into the Smad1 linker.Mol. Cell. 2007; 25 (17289590): 441-454
- Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-β pathways.Cell. 2009; 139 (19914168): 757-769
- Perioperative THR-184 and AKI after cardiac surgery.J. Am. Soc. Nephrol. 2018; 29 (29203473): 670-679
- Anti-TGF-β1 antibody therapy in patients with diabetic nephropathy.J. Am. Soc. Nephrol. 2017; 28 (27647855): 953-962
- 2-(2-Arylphenyl)benzoxazole as a novel anti-inflammatory scaffold: synthesis and biological evaluation.ACS Med. Chem. Lett. 2014; 5 (24900871): 512-516
- Novel SIRT1 activator MHY2233 improves glucose tolerance and reduces hepatic lipid accumulation in db/db mice.Bioorg. Med. Chem. Lett. 2018; 28 (29402742): 684-688
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.Adv. Drug Deliv. Rev. 2001; 46 (11259830): 3-26
- Exploration, normalization, and summaries of high density oligonucleotide array probe level data.Biostatistics. 2003; 4 (12925520): 249-264
- Linear models and empirical bayes methods for assessing differential expression in microarray experiments.Stat. Appl. Genet. Mol. Biol. 2004; 3 (16646809)3
- Controlling the false discovery rate: a practical and powerful approach to multiple testing.J. R. Stat. Soc. Ser. B Methodol. 1995; 57: 289-300
- PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update.Nucleic Acids Res. 2012; 40 (22086960): D1144-D1149
Article info
Publication history
Footnotes
This work was supported by NIDDK, National Institutes of Health, Grants 5R01-DK054740-16 and 3R01-DK054740-16S1. Funding was also provided by the University of Michigan Center for the Discovery of New Medicines directed by V. Groppi. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
This article contains Figs. S1 and S2.
Identification
Copyright
User license
Creative Commons Attribution (CC BY 4.0) |
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy